{"id":5653,"date":"2025-06-18T05:53:00","date_gmt":"2025-06-18T08:53:00","guid":{"rendered":"https:\/\/elinversordebolsillo.com.ar\/?p=5653"},"modified":"2025-06-09T10:25:52","modified_gmt":"2025-06-09T13:25:52","slug":"ipo-de-amgen","status":"publish","type":"post","link":"https:\/\/elinversordebolsillo.com.ar\/en\/ipo-de-amgen\/","title":{"rendered":"La IPO de Amgen: A 42 A\u00f1os del Hist\u00f3rico Suceso"},"content":{"rendered":"

June 18th anniversary<\/p>\n\n\n\n

On June 18, 1983, Amgen, the biotechnology company, launched its IPO. Discover its remarkable rise to today as a leading company in its field.<\/em><\/strong><\/p>\n\n\n\n

Amgen, one of the world's most prominent biotechnology companies, was founded in 1980 in Thousand Oaks, California. Its history is marked by innovation in the development of biological therapies to treat serious diseases, and its IPO (Initial Public Offering) on June 18, 1983, represented a key milestone in its growth. To understand the importance of this offering and Amgen's evolution, it is essential to review its founding, the challenges of the sector in its early years, and how the company managed to establish itself as a biotechnology giant.<\/p>\n\n\n\n

Amgen's Early Years<\/h2>\n\n\n\n

Amgen was founded by George Rathmann<\/strong>, Joseph Rubinfeld<\/strong> and William Korman<\/strong> with the vision of transforming biotechnology into a profitable industry. The company was initially created to develop innovative biotechnology-based medicines, rather than traditional pharmaceutical formulations, using genetic engineering and biological processes. In the early 1980s, the biotechnology industry was still in its early stages, with few products on the market and high uncertainty about its financial viability.<\/p>\n\n\n\n

Amgen had its first major breakthrough with the genetic recombination<\/strong> to produce erythropoietin (EPO)<\/strong>, a drug used to treat anemia in patients with chronic diseases or cancer. This was one of the first examples of modern biotechnology successfully applied to medicine, paving the way for future innovations.<\/p>\n\n\n\n

\"Ipo<\/figure>\n\n\n\n

Amgen's IPO: A Milestone in 1983<\/h2>\n\n\n\n

On June 18, 1983, Amgen went public with its stock offering<\/strong>, a momentous event that not only funded its expansion but also marked a turning point for the biotech industry in general. The IPO of Amgen<\/strong> It was one of the first major deals in the biotechnology sector, which at the time was not yet considered an established industry. In fact, few believed in the success of biotech companies due to the inherent risks involved in drug development.<\/p>\n\n\n\n

The IPO allowed Amgen to raise more than two million dollars<\/strong> and laid the foundation for its future growth. Although the shares were initially valued at $22 per share<\/strong>, the market response was positive, and Amgen's share value grew steadily, reflecting the confidence investors were beginning to place in the company.<\/p>\n\n\n\n

Amgen's Advances in the Biotechnology Industry<\/h2>\n\n\n\n

Following its IPO, Amgen continued its focus on scientific innovation<\/strong>In the 1980s, the company dedicated itself to the research and development of biotechnological treatments using genetically modified organisms. Its greatest initial success was Erypo<\/strong>, the trade name for recombinant erythropoietin, which revolutionized the treatment of anemia associated with kidney failure and other diseases.<\/p>\n\n\n\n

In the 1990s, Amgen diversified its portfolio with other innovative products, such as Neupogen<\/strong> (filgrastim), used to stimulate white blood cell production in cancer patients receiving chemotherapy. These drugs marked the beginning of Amgen's global expansion, making it one of the leading companies in the biotechnology industry.<\/p>\n\n\n\n

Over the following decades, the company expanded its presence internationally, developing more treatments in areas such as oncology<\/strong>, the cardiology<\/strong> and the hematology<\/strong>, and began acquiring other biotechnology and pharmaceutical companies to strengthen its portfolio.<\/p>\n\n\n\n

\"Banner<\/figure>\n\n\n\n

Amgen in the 21st Century<\/h2>\n\n\n\n

In the 21st century, Amgen has maintained its position as a leader in biotechnology, distinguished by its continuous development of innovative medicines, many of which have become essential treatments for various medical conditions. Over the years, the company has invested heavily in research and development<\/strong>, focusing on key areas such as personalized medicine<\/strong>, the gene therapies<\/strong> and the immunotherapy<\/strong>.<\/p>\n\n\n\n

Amgen has also worked to diversify its focus on healthcare, with a strong emphasis on advanced biotechnology<\/strong>, including the precision medicine<\/strong> and the development of new monoclonal antibodies<\/strong>The company remains at the forefront of molecular biotechnology<\/strong> with products such as Prolia<\/strong> and Repatha<\/strong>, which are biological drugs used to treat bone and cardiovascular diseases, respectively.<\/p>\n\n\n\n

International Expansion and Strategic Acquisitions<\/h2>\n\n\n\n

Amgen has pursued a growth strategy that includes international expansion and the acquisition of key companies to broaden its portfolio. In 2012, it acquired the company Onyx Pharmaceuticals<\/strong>, which allowed it to fully enter the market of oncology<\/strong>, one of the fastest-growing areas in biotechnology. Furthermore, over the past decade, Amgen has established strategic alliances<\/strong> with other major biotechnology and pharmaceutical companies to enhance their research capabilities and expand their global presence.<\/p>\n\n\n\n

In 2020, the company continued its focus on innovation with products such as Aimovig<\/strong>, a migraine treatment that is also among the most innovative of its kind. Amgen continues to demonstrate that, despite industry competition, it has the resources and capability to stay ahead.<\/p>\n\n\n\n

\"El<\/span>
\n

Get all three books now to make ends meet!<\/mark><\/a><\/p>\n<\/div><\/div>\n\n\n\n

The Future of Amgen<\/h2>\n\n\n\n

Today, Amgen faces several challenges, such as competition in the biosimilar market and pressure to control costs in the pharmaceutical industry. However, the company has maintained its focus on scientific innovation<\/strong> and in the development of new biotechnological treatments to improve the lives of patients. The growth of its research platform<\/strong> and your investment in advanced biotechnology<\/strong> remain their main areas of focus, while ensuring that they maintain a balance with market challenges.<\/p>\n\n\n\n

As the world continues to evolve, Amgen remains a central pillar in modern biotechnology, proving that investment in innovation and development<\/strong> remains key to long-term success. Amgen's IPO in 1983 was the starting point in a success story that continues today, and its impact on the biotechnology world remains profound.<\/p>\n\n\n\n

In summary, Amgen<\/strong> Not only has she left her mark on the biotechnology industry, but she has also been a pioneer in demonstrating that the development of innovative treatments can have an impact positive and lasting in modern medicine<\/strong>.<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

You might also be interested in:<\/strong><\/td><\/tr>
The Secrets to Starting to Invest in the Stock Market for Beginners<\/a><\/td><\/tr>
How to achieve your financial goals and achieve financial freedom<\/a><\/td><\/tr>
Frequently asked questions about our Financial Mentoring<\/a><\/td><\/tr>
Choosing quality financial services is essential. How do you get them?<\/a><\/td><\/tr>
Reasons why taking financial mentoring is essential<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Both you and your company can also invest in quality companies.<\/h2>\n\n\n\n

In the Financial Mentoring<\/a> With El Inversor de Bolsillo\u00ae you can learn while you invest, and we'll guide you according to your needs.<\/strong> Financial consulting for individuals includes one-on-one advisory sessions, online courses, stock market reports and everything you need to your investment is a success<\/strong>, so much investing in Argentina as in any other part of the world.<\/strong>
There are different monthly plans of according to your circumstances and your budget<\/strong>The most important thing is that whichever plan you choose, you'll never be alone<\/strong>We will accompany you in your learning so that you can invest successfully.<\/strong><\/p>\n\n\n\n

Getting the best financing for your business isn't easy. And you're also focused on improving your business, so financial matters can be difficult. Don't worry, we're here to help.
With the Financial Optimization Program<\/a> From El Inversor de Bolsillo\u00ae, we evaluate the company and give you specific suggestions to optimize the performance of your current balances and reduce your interest burden. <\/strong>We help you manage the registration in a Reciprocal Guarantee Society and get the best rates on the market<\/strong>. After the three free months have passed, a set number of monthly hours of financial consulting is provided.<\/p>\n\n\n\n

If you want to learn more about how to invest risk-free, visit our website. www.elinversordebolsillo.com.ar<\/a> either our YouTube channel<\/a>.<\/p>\n\n\n\n

<\/p>\n\n\n\n